Nuvectis Pharma, Inc. (NVCT): Total Liabilities
$13.30M
As of 2025-12-31
$13.29M
As of 2026-06-30
+29.1%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.30M | +49.5% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $8.89M | +27.3% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $6.98M | +12.9% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $6.19M | +155.7% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $2.42M | n/a | 2023-03-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $13.30M | +49.5% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $7.44M | n/m |
| Equillium, Inc. (EQ) | 2025-12-31 | $3.29M | -49.7% |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $11.13M | -72.7% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $8.26M | +15.7% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $29.63M | +5.4% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $21.24M | -19.4% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $2.40M | -83.8% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $7.04M | -0.3% |
Compare NVCT, VBIO, EQ, TVRD side by side · Screen every company in Pharmaceutical Preparations ↗